LI
RXRX icon

Louisbourg Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Louisbourg Investments’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46K Sell
670
-500
-43% -$1.67K ﹤0.01% 190
2026
Q1 		$3.59K Buy
1,170
+695
+146% +$2.69K ﹤0.01% 189
2025
Q4 		$1.94K Buy
+475
New +$2.35K ﹤0.01% 194

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return
TMC
Themes Management Co Greenwich, Connecticut $151M AUM
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Louisbourg Investments's RXRX Position: Q2 2026 in Review

Louisbourg Investments reduced its Recursion Pharmaceuticals (RXRX) stake by 43% in Q2 2026, selling an estimated $1.67K and leaving 670 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #190.

Louisbourg Investments first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.59K in Q1 2026. 58 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Louisbourg Investments held 670 shares of Recursion Pharmaceuticals worth $2.46K as of Q2 2026.
  • Louisbourg Investments sold 500 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.67K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Louisbourg Investments's portfolio in Q2 2026, its #190 holding.
  • Louisbourg Investments first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Louisbourg Investments's Recursion Pharmaceuticals position peaked at $3.59K in Q1 2026.
  • 58 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Louisbourg Investments's 13F filing for Q2 2026, filed 23 Jul 2026.